Literature DB >> 72803

Anomalous lymphocyte-antigen reaction in relatives of multiple sclerosis patients. A study of a possible genetic factor in the disease.

E J Field, H J Meyer-Rienecker, B K Shenton, H L Jenssen, H Köhler.   

Abstract

A combined familial study of multiple sclerosis (MS) in England and in the Rostock area of the GDR using the macrophage electrophoretic mobility (MEM)-LAD test embracing 132 relatives has revealed a closely similar pattern of distribution of "anomalous" LAD (Linoleic Acid Depression) values in relatives (77% type of reaction) to that originally reported in the British study. The anomaly in predominantly associated with females--all mothers of MS patients being affected, whilst daughters and sisters are also represented. In addition unusual full MS type of reaction (90% reduction) has been found in some children related to patients. There is clearly a genetic element in the development of MS probably mainfested in the inborn mishandling of unsaturated fatty acids suggested by Thompson; no recognizable pattern of inheritance is noticeable even within the combined material. There is evidence that the metabolic anomaly alone does not inevitably lead to MS, and the full abnormality may be present at an early age. A survey about the examinations and a selection of characteristic family trees of MS are given, illustrating the manner in which the 77% type anomaly is distributed with occasional omission of a generation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 72803     DOI: 10.1007/BF00312947

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Letter: A rational prophylactic therapy for multiple sclerosis?

Authors:  E J Field
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

2.  [Aspects of the diagnostic criterions and the classification of the multiple sclerosis (author's transl)].

Authors:  H J Meyer-Rienecker; R M Olischer
Journal:  Fortschr Neurol Psychiatr Grenzgeb       Date:  1974-08

3.  Letter: Effect of polyunsaturated fatty acids on lymphocyte activity.

Authors:  E J Field; B K Shenton
Journal:  Br Med J       Date:  1973-12-22

4.  Genetical factors in the aetiology of multiple sclerosis.

Authors:  R J Berry
Journal:  Acta Neurol Scand       Date:  1969       Impact factor: 3.209

5.  Histocompatibility determinants in multiple sclerosis.

Authors:  C Jersild; B Dupont; T Fog; P J Platz; A Svejgaard
Journal:  Transplant Rev       Date:  1975

6.  Lymphocyte sensitisation: an in-vitro test for cancer?

Authors:  E J Field; E A Caspary
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

7.  The linoleic acid depression (LAD) test for multiple sclerosis using the macrophage electrophoretic mobility (MEM) test.

Authors:  H L Jenssen; H J Meyer-Rienecker; H Köhler; J K Günther
Journal:  Acta Neurol Scand       Date:  1976-01       Impact factor: 3.209

8.  Allergic encephalomyelitis induced by brain antigen after deficiency in polyunsaturated fatty acids during myelination. Is multiple sclerosis a nutritive disorder?

Authors:  J Clausen; J Moller
Journal:  Acta Neurol Scand       Date:  1967       Impact factor: 3.209

9.  [Cytopherometry in neurologic diseases (author's transl)].

Authors:  H J Meyer-Rienecker; H L Jenssen; H Köhler; H Werner
Journal:  Fortschr Neurol Psychiatr Grenzgeb       Date:  1977-11

10.  Mixed lymphocyte reaction in multiple sclerosis.

Authors:  E J Field; B K Shenton; H Meyer-Rienecker
Journal:  Acta Neurol Scand       Date:  1976-08       Impact factor: 3.209

View more
  3 in total

1.  Polyunsaturated fatty acids and colchicine in multiple sclerosis.

Authors: 
Journal:  Br Med J       Date:  1979-02-10

2.  Spontaneous and mutagen induced sister chromatid exchange in multiple sclerosis.

Authors:  M S Newton; C M Steel; H J Evans; B Pentland
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

3.  Multiple sclerosis: treatment and prophylaxis.

Authors:  E J Field
Journal:  J R Soc Med       Date:  1979-07       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.